-
1 Comment
Carna Biosciences, Inc is currently in a long term uptrend where the price is trading 18.4% above its 200 day moving average.
From a valuation standpoint, the stock is 79.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.8.
Carna Biosciences, Inc's total revenue sank by 17.2% to $286M since the same quarter in the previous year.
Its net income has dropped by 62.2% to $-462M since the same quarter in the previous year.
Based on the above factors, Carna Biosciences, Inc gets an overall score of 2/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| ISIN | JP3220550002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Market Cap | 4B |
|---|---|
| PE Ratio | None |
| Beta | 0.41 |
| Target Price | 3400 |
| Dividend Yield | None |
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo assay; and cell-based assay services which include NanoBRET TE intracellular kinase assay and split luciferase protein-protein interaction detection assay. In addition, it engages in developing monzosertib, an orally bioavailable small molecule inhibitor of cell division cycle 7 (CDC7) kinase that is in Phase 1 to treat various cancer cell lines including solid and blood cancers; docirbrutinib, an orally bioavailable, non-covalent pan-inhibitor of wild type and mutant Bruton's tyrosine kinases for the treatment of chronic lymphocytic leukemia and other B-cell malignancies; and sofnobrutinib, a non-covalent Bruton's tyrosine kinases which is in clinical development to treat inflammatory and immune disorders. Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4572.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
